FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:86-93 January 8, 1998 Number 2 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The high-density lipoprotein (HDL) cholesterol concentration is inversely related to the risk of coronary artery disease. The cholesteryl ester transfer protein (CETP) has a central role in the metabolism of this lipoprotein and may therefore alter the susceptibility to atherosclerosis.

Methods The DNA of 807 men with angiographically documented coronary atherosclerosis was analyzed for the presence of a polymorphism in the gene coding for CETP. The presence of this DNA variation was referred to as B1, and its absence as B2. All patients participated in a cholesterol-lowering trial designed to induce the regression of coronary atherosclerosis and were randomly assigned to treatment with either pravastatin or placebo for two years.

Results The B1 variant of the CETP gene was associated with both higher plasma CETP concentrations (mean [±SD], 2.29±0.62 µg per milliliter for the B1B1 genotype vs. 1.76±0.51 µg per milliliter for the B2B2 genotype) and lower HDL cholesterol concentrations (34±8 vs. 39±10 mg per deciliter). In addition, we observed a significant dose-dependent association between this marker and the progression of coronary atherosclerosis in the placebo group (decrease in mean luminal diameter: 0.14±0.21 mm for the B1B1 genotype, 0.10±0.20 mm for the B1B2 genotype, and 0.05±0.22 mm for the B2B2 genotype). This association was abolished by pravastatin. Pravastatin therapy slowed the progression of coronary atherosclerosis in B1B1 carriers but not in B2B2 carriers (representing 16 percent of the patients taking pravastatin).

Conclusions There is a significant relation between variation at the CETP gene locus and the progression of coronary atherosclerosis that is independent of plasma HDL cholesterol levels and the activities of lipolytic plasma enzymes. This common DNA variant appears to predict whether men with coronary artery disease will benefit from treatment with pravastatin to delay the progression of coronary atherosclerosis.

Source Information

From the Departments of Vascular Medicine (J.A.K., J.J.P.K.) and Cardiology (K.I.L.), Academic Medical Center, Amsterdam, the Netherlands; the Departments of Cardiology (J.W.J., A.V.G.B.), Biostatistics (A.H.Z.), and Human Genetics (P. de K.), Leiden University, Leiden, the Netherlands; the Lipoproteins and Atherosclerosis Group, Ottawa Heart Institute, Ottawa, Ont., Canada (R.M.); and the Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands (A.V.G.B.).

Address reprint requests to Dr. Kastelein at the Academic Medical Center, Department of Vascular Medicine (Rm. G1-123), Meibergdreef 9, P.O. Box 22.700, 1105 AZ Amsterdam, the Netherlands.

Full Text of this Article

Related Letters:

Polymorphism of the Cholesteryl Ester Transfer Protein Gene
Goldstein M. R., Dullaart R. P.F., van Tol A., Kuivenhoven J. A., Kastelein J. J.P.
Extract | Full Text  
N Engl J Med 1998; 338:1624-1626, May 28, 1998. Correspondence

This article has been cited by other articles:

• Bruschke, A. V.G., Jukema, J. W. (2008). Aggressive Therapy Is Not Always the Best Therapy. J Am Coll Cardiol 52: 921-923 [Full Text]  
• de Haan, W., de Vries-van der Weij, J., van der Hoorn, J. W.A., Gautier, T., van der Hoogt, C. C., Westerterp, M., Romijn, J. A., Jukema, J. W., Havekes, L. M., Princen, H. M.G., Rensen, P. C.N. (2008). Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin. Circulation 117: 2515-2522 [Abstract] [Full Text]  
• Hopkins, R. O., Weaver, L. K., Valentine, K. J., Mower, C., Churchill, S., Carlquist, J. (2007). Apolipoprotein E Genotype and Response of Carbon Monoxide Poisoning to Hyperbaric Oxygen Treatment. Am. J. Respir. Crit. Care Med. 176: 1001-1006 [Abstract] [Full Text]  
• Zeller, M., Masson, D., Farnier, M., Lorgis, L., Deckert, V., Pais de Barros, J.-P., Desrumaux, C., Sicard, P., Grober, J., Blache, D., Gambert, P., Rochette, L., Cottin, Y., Lagrost, L. (2007). High Serum Cholesteryl Ester Transfer Rates and Small High-Density Lipoproteins Are Associated With Young Age in Patients With Acute Myocardial Infarction. J Am Coll Cardiol 50: 1948-1955 [Abstract] [Full Text]  
• Porchay-Balderelli, I., Pean, F., Bellili, N., Jaziri, R., Marre, M., Fumeron, F., for the DIABHYCAR Study Group, (2007). The CETP TaqIB Polymorphism Is Associated With the Risk of Sudden Death in Type 2 Diabetic Patients. Diabetes Care 30: 2863-2867 [Abstract] [Full Text]  
• Morgan, T. M., Krumholz, H. M., Lifton, R. P., Spertus, J. A. (2007). Nonvalidation of Reported Genetic Risk Factors for Acute Coronary Syndrome in a Large-Scale Replication Study. JAMA 297: 1551-1561 [Abstract] [Full Text]  
• Iakoubova, O. A., Tong, C. H., Chokkalingam, A. P., Rowland, C. M., Kirchgessner, T. G., Louie, J. Z., Ploughman, L. M., Sabatine, M. S., Campos, H., Catanese, J. J., Leong, D. U., Young, B. A., Lew, D., Tsuchihashi, Z., Luke, M. M., Packard, C. J., Zerba, K. E., Shaw, P. M., Shepherd, J., Devlin, J. J., Sacks, F. M. (2006). Asp92Asn Polymorphism in the Myeloid IgA Fc Receptor Is Associated With Myocardial Infarction in Two Disparate Populations: CARE and WOSCOPS. Arterioscler. Thromb. Vasc. Bio. 26: 2763-2768 [Abstract] [Full Text]  
• Westerterp, M., van der Hoogt, C. C., de Haan, W., Offerman, E. H., Dallinga-Thie, G. M., Jukema, J. W., Havekes, L. M., Rensen, P. C.N. (2006). Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice. Arterioscler. Thromb. Vasc. Bio. 26: 2552-2559 [Abstract] [Full Text]  
• Hedgecoe, A. (2006). Pharmacogenetics as Alien Science: Alzheimer's Disease, Core Sets and Expectations. Social Studies of Science 36: 723-752 [Abstract]  
• Borggreve, S. E., Hillege, H. L., Wolffenbuttel, B. H. R., de Jong, P. E., Zuurman, M. W., van der Steege, G., van Tol, A., Dullaart, R. P. F., on behalf of the PREVEND Study Group, (2006). An Increased Coronary Risk Is Paradoxically Associated with Common Cholesteryl Ester Transfer Protein Gene Variations That Relate to Higher High-Density Lipoprotein Cholesterol: A Population-Based Study. J. Clin. Endocrinol. Metab. 91: 3382-3388 [Abstract] [Full Text]  
• Rensen, P. C.N., Havekes, L. M. (2006). Cholesteryl Ester Transfer Protein Inhibition: Effect on Reverse Cholesterol Transport?. Arterioscler. Thromb. Vasc. Bio. 26: 681-684 [Full Text]  
• Frisdal, E., Klerkx, A. H.E.M., Goff, W. L., Tanck, M. W.T., Lagarde, J.-P., Jukema, J. W., Kastelein, J. J.P., Chapman, M. J., Guerin, M. (2005). Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study. Hum Mol Genet 14: 2607-2618 [Abstract] [Full Text]  
• Johnson, J. A., Cavallari, L. H. (2005). Cardiovascular pharmacogenomics. Exp Physiol 90: 283-289 [Abstract] [Full Text]  
• Boekholdt, S.M., Sacks, F.M., Jukema, J.W., Shepherd, J., Freeman, D.J., McMahon, A.D., Cambien, F., Nicaud, V., de Grooth, G.J., Talmud, P.J., Humphries, S.E., Miller, G.J., Eiriksdottir, G., Gudnason, V., Kauma, H., Kakko, S., Savolainen, M.J., Arca, M., Montali, A., Liu, S., Lanz, H.J., Zwinderman, A.H., Kuivenhoven, J.A., Kastelein, J.J.P. (2005). Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment: Individual Patient Meta-Analysis of 13 677 Subjects. Circulation 111: 278-287 [Abstract] [Full Text]  
• de Grooth, G. J., Klerkx, A. H. E. M., Stroes, E. S. G., Stalenhoef, A. F. H., Kastelein, J. J. P., Kuivenhoven, J. A. (2004). A review of CETP and its relation to atherosclerosis. J. Lipid Res. 45: 1967-1974 [Abstract] [Full Text]  
• Lusis, A. J., Fogelman, A. M., Fonarow, G. C. (2004). Genetic Basis of Atherosclerosis: Part II: Clinical Implications. Circulation 110: 2066-2071 [Full Text]  
• Keavney, B., Palmer, A., Parish, S., Clark, S., Youngman, L., Danesh, J., McKenzie, C., Delepine, M., Lathrop, M., Peto, R., Collins, R., for the International Studies of Infarct Survival, (2004). Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk. Int J Epidemiol 33: 1002-1013 [Abstract] [Full Text]  
• Gibbons, G. H., Liew, C. C., Goodarzi, M. O., Rotter, J. I., Hsueh, W. A., Siragy, H. M., Pratt, R., Dzau, V. J. (2004). Genetic Markers: Progress and Potential for Cardiovascular Disease. Circulation 109: IV-47-IV-58 [Full Text]  
• Chasman, D. I., Posada, D., Subrahmanyan, L., Cook, N. R., Stanton, V. P. Jr, Ridker, P. M (2004). Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction. JAMA 291: 2821-2827 [Abstract] [Full Text]  
• Humphries, S. E., Ridker, P. M., Talmud, P. J. (2004). Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation?. Arterioscler. Thromb. Vasc. Bio. 24: 628-636 [Abstract] [Full Text]  
• Shoulders, C.C., Jones, E.L., Naoumova, R.P. (2004). Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet 13: R149-160 [Abstract] [Full Text]  
• Gotto, A. M. Jr, Brinton, E. A. (2004). Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report and update. J Am Coll Cardiol 43: 717-724 [Abstract] [Full Text]  
• de Grooth, G. J., Zerba, K. E., Huang, S.-P., Tsuchihashi, Z., Kirchgessner, T., Belder, R., Vishnupad, P., Hu, B., Klerkx, A. H. E. M., Zwinderman, A. H., Jukema, J. W., Sacks, F. M., Kastelein, J. J. P., Kuivenhoven, J. A. (2004). The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: A prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. J Am Coll Cardiol 43: 854-857 [Abstract] [Full Text]  
• Tobin, M. D, Braund, P. S, Burton, P. R, Thompson, J. R, Steeds, R., Channer, K., Cheng, S., Lindpaintner, K., Samani, N. J (2004). Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur Heart J 25: 459-467 [Abstract] [Full Text]  
• Freeman, D. J, Samani, N. J, Wilson, V., McMahon, A. D, Braund, P. S, Cheng, S., Caslake, M. J, Packard, C. J, Gaffney, D., on behalf of the West of Scotland Study Group, (2003). A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur Heart J 24: 1833-1842 [Abstract] [Full Text]  
• Hedgecoe, A. M. (2003). Terminology and the Construction of Scientific Disciplines: The Case of Pharmacogenomics. Science Technology Human Values 28: 513-537 [Abstract]  
• Dzau, V. (2003). Risk assessment in cardiovascular disease: from traditional risk factors to genomics. Eur Heart J Suppl 5: F48-F55 [Abstract]  
• Nabel, E. G. (2003). Cardiovascular Disease. NEJM 349: 60-72 [Full Text]  
• Boekholdt, S. M., Thompson, J. F. (2003). Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J. Lipid Res. 44: 1080-1093 [Abstract] [Full Text]  
• Blankenberg, S., Rupprecht, H. J., Bickel, C., Jiang, X.-C., Poirier, O., Lackner, K. J., Meyer, J.u., Cambien, F., Tiret, L., AtheroGene Investigators, (2003). Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. J Am Coll Cardiol 41: 1983-1989 [Abstract] [Full Text]  
• Anderson, J. L., Carlquist, J. F. (2003). Genetic polymorphisms of hepatic lipase and cholesteryl ester transfer protein, intermediate phenotypes, and coronary risk: Do they add up yet?. J Am Coll Cardiol 41: 1990-1993 [Full Text]  
• Hedgecoe, A., Martin, P. (2003). The Drugs Don't Work: Expectations and the Shaping of Pharmacogenetics. Social Studies of Science 33: 327-364 [Abstract]  
• Boekholdt, S. M., Agema, W. R.P., Peters, R. J.G., Zwinderman, A. H., van der Wall, E. E., Reitsma, P. H., Kastelein, J. J.P., Jukema, J. W. (2003). Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events. Circulation 107: 2416-2421 [Abstract] [Full Text]  
• van Venrooij, F. V., Stolk, R. P., Banga, J.-D., Sijmonsma, T. P., van Tol, A., Erkelens, D. W., Dallinga-Thie, G. M. (2003). Common Cholesteryl Ester Transfer Protein Gene Polymorphisms and the Effect of Atorvastatin Therapy in Type 2 Diabetes. Diabetes Care 26: 1216-1223 [Abstract] [Full Text]  
• Anderson, J. L., Carlquist, J. F., Home, B. D., Muhlestein, J. B. (2003). Cardiovascular Pharmacogenomics: Current Status, Future Prospects. J CARDIOVASC PHARMACOL THER 8: 71-83 [Abstract]  
• Bluher, M., Lubben, G., Paschke, R. (2003). Analysis of the Relationship Between the Pro12Ala Variant in the PPAR-{gamma}2 Gene and the Response Rate to Therapy With Pioglitazone in Patients With Type 2 Diabetes. Diabetes Care 26: 825-831 [Abstract] [Full Text]  
• Evans, W. E., McLeod, H. L. (2003). Pharmacogenomics -- Drug Disposition, Drug Targets, and Side Effects. NEJM 348: 538-549 [Full Text]  
• Bonetti, P.O, Lerman, L.O, Napoli, C, Lerman, A (2003). Statin effects beyond lipid lowering--are they clinically relevant?. Eur Heart J 24: 225-248 [Full Text]  
• Barter, P. J., Brewer, H. B. Jr, Chapman, M. J., Hennekens, C. H., Rader, D. J., Tall, A. R. (2003). Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis. Arterioscler. Thromb. Vasc. Bio. 23: 160-167 [Abstract] [Full Text]  
• Gervais, M., Pons, S., Nicoletti, A., Cosson, C., Giudicelli, J.-F., Richer, C. (2003). Fluvastatin Prevents Renal Dysfunction and Vascular NO Deficit in Apolipoprotein E-Deficient Mice. Arterioscler. Thromb. Vasc. Bio. 23: 183-189 [Abstract] [Full Text]  
• Klerkx, A. H.E.M., Tanck, M. W.T., Kastelein, J. J.P., Molhuizen, H. O.F., Jukema, J. W., Zwinderman, A. H., Kuivenhoven, J. A. (2003). Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C->A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet 12: 111-123 [Abstract] [Full Text]  
• Yamada, Y., Izawa, H., Ichihara, S., Takatsu, F., Ishihara, H., Hirayama, H., Sone, T., Tanaka, M., Yokota, M. (2002). Prediction of the Risk of Myocardial Infarction from Polymorphisms in Candidate Genes. NEJM 347: 1916-1923 [Abstract] [Full Text]  
• Brown, B. G., Cheung, M. C., Lee, A. C., Zhao, X.-Q., Chait, A. (2002). Antioxidant Vitamins and Lipid Therapy: End of a Long Romance?. Arterioscler. Thromb. Vasc. Bio. 22: 1535-1546 [Abstract] [Full Text]  
• Kennedy, H. L., Rosenson, R. S. (2002). Physicians' interpretation of "class effects": A need for thoughtful re-evaluation. J Am Coll Cardiol 40: 19-26 [Abstract] [Full Text]  
• Brousseau, M. E., O'Connor, J. J. Jr, Ordovas, J. M., Collins, D., Otvos, J. D., Massov, T., McNamara, J. R., Rubins, H. B., Robins, S. J., Schaefer, E. J. (2002). Cholesteryl Ester Transfer Protein TaqI B2B2 Genotype Is Associated With Higher HDL Cholesterol Levels and Lower Risk of Coronary Heart Disease End Points in Men With HDL Deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler. Thromb. Vasc. Bio. 22: 1148-1154 [Abstract] [Full Text]  
• Kawasaki, I., Tahara, H., Emoto, M., Shoji, T., Nishizawa, Y. (2002). Relationship Between TaqIB Cholesteryl Ester Transfer Protein Gene Polymorphism and Macrovascular Complications in Japanese Patients With Type 2 Diabetes. Diabetes 51: 871-874 [Abstract] [Full Text]  
• Agema, W. R. P., Jukema, J. W., Pimstone, S. N., Kastelein, J. J. P. (2001). Genetic aspects of restenosis after percutaneous coronary interventions;towards more tailored therapy. Eur Heart J 22: 2058-2074  
• Francke, S., Manraj, M., Lacquemant, C., Lecoeur, C., Lepretre, F., Passa, P., Hebe, A., Corset, L., Yan, S. L. K., Lahmidi, S., Jankee, S., Gunness, T. K., Ramjuttun, U. S., Balgobin, V., Dina, C., Froguel, P. (2001). A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. Hum Mol Genet 10: 2751-2765 [Abstract] [Full Text]  
• Higgins, M (2001). Patients, families and populations at high risk for coronary heart disease. Eur Heart J 22: 1682-1690  
• Talmud, P. J., Berglund, L., Hawe, E. M., Waterworth, D. M., Isasi, C. R., Deckelbaum, R. E., Starc, T., Ginsberg, H. N., Humphries, S. E., Shea, S. (2001). Age-Related Effects of Genetic Variation on Lipid Levels: The Columbia University BioMarkers Study. Pediatrics 108: e50-50 [Abstract] [Full Text]  
• Teupser, D., Rupprecht, W., Lohse, P., Thiery, J. (2001). Fluorescence-based Detection of the CETP TaqIB Polymorphism: False Positives with the TaqMan-based Exonuclease Assay Attributable to a Previously Unknown Gene Variant. Clin. Chem. 47: 852-857 [Abstract] [Full Text]  
• Shi, M. M., Bleavins, M. R., de la Iglesia, F. A. (2001). Pharmacogenetic Application in Drug Development and Clinical Trials. Drug Metab. Dispos. 29: 591-595 [Abstract] [Full Text]  
• Kastrati, A., Schomig, A. (2001). Good medicines for bad genes. Eur Heart J 22: 523-525  
• Hadjadj, S., Gallois, Y., Simard, G., Bouhanick, B., Passa, P., Grimaldi, A., Drouin, P., Tichet, J., Marre, M. (2000). Lack of relationship in long-term type 1 diabetic patients between diabetic nephropathy and polymorphisms in apolipoprotein {varepsilon}, lipoprotein lipase and cholesteryl ester transfer protein. Nephrol Dial Transplant 15: 1971-1976 [Abstract] [Full Text]  
• Agerholm-Larsen, B., Tybjarg-Hansen, A., Schnohr, P., Steffensen, R., Nordestgaard, B. G. (2000). Common Cholesteryl Ester Transfer Protein Mutations, Decreased HDL Cholesterol, and Possible Decreased Risk of Ischemic Heart Disease : The Copenhagen City Heart Study. Circulation 102: 2197-2203 [Abstract] [Full Text]  
• WILKINS, M. R, ROSES, A. D, CLIFFORD, C P. (2000). Pharmacogenetics and the treatment of cardiovascular disease. Heart 84: 353-354 [Full Text]  
• Crisan, D., Carr, J. (2000). Angiotensin I-Converting Enzyme: Genotype and Disease Associations. J. Mol. Diagn. 2: 105-115 [Full Text]  
• Talmud, P. J., Edwards, K. L., Turner, C. M., Newman, B., Palmen, J. M., Humphries, S. E., Austin, M. A. (2000). Linkage of the Cholesteryl Ester Transfer Protein (CETP) Gene to LDL Particle Size : Use of a Novel Tetranucleotide Repeat Within the CETP Promoter. Circulation 101: 2461-2466 [Abstract] [Full Text]  
• Diekman, M. J. M., Anghelescu, N., Endert, E., Bakker, O., Wiersinga, W. M. (2000). Changes in Plasma Low-Density Lipoprotein (LDL)- and High-Density Lipoprotein Cholesterol in Hypo- and Hyperthyroid Patients Are Related to Changes in Free Thyroxine, Not to Polymorphisms in LDL Receptor or Cholesterol Ester Transfer Protein Genes. J. Clin. Endocrinol. Metab. 85: 1857-1862 [Abstract] [Full Text]  
• Ordovas, J. M., Cupples, L. A., Corella, D., Otvos, J. D., Osgood, D., Martinez, A., Lahoz, C., Coltell, O., Wilson, P. W. F., Schaefer, E. J. (2000). Association of Cholesteryl Ester Transfer Protein-TaqIB Polymorphism With Variations in Lipoprotein Subclasses and Coronary Heart Disease Risk : The Framingham Study. Arterioscler. Thromb. Vasc. Bio. 20: 1323-1329 [Abstract] [Full Text]  
• Drews, J. (2000). Drug Discovery: A Historical Perspective. Science 287: 1960-1964 [Abstract] [Full Text]  
• Watts, G. F., Riches, F. M., Humphries, S. E., Talmud, P. J., van Bockxmeer, F. M. (2000). Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity. J. Lipid Res. 41: 481-488 [Abstract] [Full Text]  
• Dachet, C., Poirier, O., Cambien, F., Chapman, J., Rouis, M. (2000). New Functional Promoter Polymorphism, CETP/-629, in Cholesteryl Ester Transfer Protein (CETP) Gene Related to CETP Mass and High Density Lipoprotein Cholesterol Levels : Role of Sp1/Sp3 in Transcriptional Regulation. Arterioscler. Thromb. Vasc. Bio. 20: 507-515 [Abstract] [Full Text]  
• Sugano, M., Sawada, S., Tsuchida, K., Makino, N., Kamada, M. (2000). Low density lipoproteins develop resistance to oxidative modification due to inhibition of cholesteryl ester transfer protein by a monoclonal antibody. J. Lipid Res. 41: 126-133 [Abstract] [Full Text]  
• Evans, W. E., Relling, M. V. (1999). Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science 286: 487-491 [Abstract] [Full Text]  
• Cheng, S., Grow, M. A., Pallaud, C., Klitz, W., Erlich, H. A., Visvikis, S., Chen, J. J., Pullinger, C. R., Malloy, M. J., Siest, G., Kane, J. P. (1999). A Multilocus Genotyping Assay for Candidate Markers of Cardiovascular Disease Risk. Genome Res 9: 936-949 [Abstract] [Full Text]  
• Lewis-Barned, N. J., Sutherland, W. H. F., Walker, R. J., Walker, H. L., de Jong, S. A., Edwards, E. A., Markham, V. H. (1999). Plasma Cholesterol Esterification And Transfer, the Menopause, And Hormone Replacement Therapy in Women. J. Clin. Endocrinol. Metab. 84: 3534-3538 [Abstract] [Full Text]  
• Durlach, A., Clavel, C., Girard-Globa, A., Durlach, V. (1999). Sex-Dependent Association of a Genetic Polymorphism of Cholesteryl Ester Transfer Protein with High-Density Lipoprotein Cholesterol and Macrovascular Pathology in Type II Diabetic Patients. J. Clin. Endocrinol. Metab. 84: 3656-3659 [Abstract] [Full Text]  
• Riemens, S. C., Van Tol, A., Stulp, B. K., Dullaart, R. P. F. (1999). Influence of insulin sensitivity and the TaqIB cholesteryl ester transfer protein gene polymorphism on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities and their response to hyperinsulinemia in non-diabetic men. J. Lipid Res. 40: 1467-1474 [Abstract] [Full Text]  
• JUKEMA, J W. (1999). Matching treatment to the genetic basis of (lipid) disorder in patients with coronary artery disease. Heart 82: 126-127 [Full Text]  
• Collins, F. S. (1999). Medical and Societal Consequences of the Human Genome Project. NEJM 341: 28-37 [Full Text]  
• Pahor, M., Elam, M. B., Garrison, R. J., Kritchevsky, S. B., Applegate, W. B. (1999). Emerging Noninvasive Biochemical Measures to Predict Cardiovascular Risk. Arch Intern Med 159: 237-245 [Abstract] [Full Text]  
• Pratt, R. E., Dzau, V. J. (1999). Genomics and Hypertension : Concepts, Potentials, and Opportunities. Hypertension 33: 238-247 [Abstract] [Full Text]  
• Goldstein, M. R., Dullaart, R. P.F., van Tol, A., Kuivenhoven, J. A., Kastelein, J. J.P. (1998). Polymorphism of the Cholesteryl Ester Transfer Protein Gene. NEJM 338: 1624-1626 [Full Text]  
• Altshuler, D., Kruglyak, L., Lander, E. (1998). Genetic Polymorphisms and Disease. NEJM 338: 1626-1626 [Full Text]  
• Rosenthal, N., Schwartz, R. S. (1998). In Search of Perverse Polymorphisms. NEJM 338: 122-124 [Full Text]